QTRX Quote, Financials, Valuation and Earnings

Electromed has a net margin of -27.76% compared to Quanterix's net margin of 10.05%. Quanterix's return on equity of -11.45% beat Electromed's return on equity of 15.62%.

Quanterix has a consensus price target of $21.80, signalling upside risk potential of 107.42%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 19.01%. Given that Quanterix has higher upside potential than Electromed, analysts believe Quanterix is more attractive than Electromed.

Quanterix has a beta of 1.300, which suggesting that the stock is 29.975% more volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are larger than Electromed quarterly revenues of $14.7M. Quanterix's net income of -$9.5M is lower than Electromed's net income of $1.5M. Notably, Quanterix's price-to-earnings ratio is -- while Electromed's PE ratio is 38.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 3.12x versus 4.33x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Hologic has a net margin of -27.76% compared to Quanterix's net margin of 18.08%. Quanterix's return on equity of -11.45% beat Hologic's return on equity of 16.05%.

Quanterix has a consensus price target of $21.80, signalling upside risk potential of 107.42%. On the other hand Hologic has an analysts' consensus of $85.85 which suggests that it could grow by 19.82%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Quanterix has a beta of 1.300, which suggesting that the stock is 29.975% more volatile than S&P 500. In comparison Hologic has a beta of 0.958, suggesting its less volatile than the S&P 500 by 4.165%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are smaller than Hologic quarterly revenues of $988M. Quanterix's net income of -$9.5M is lower than Hologic's net income of $178.6M. Notably, Quanterix's price-to-earnings ratio is -- while Hologic's PE ratio is 21.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 3.12x versus 4.22x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -27.76% compared to Quanterix's net margin of 99.62%. Quanterix's return on equity of -11.45% beat Nuwellis's return on equity of -918.02%.

Quanterix has a consensus price target of $21.80, signalling upside risk potential of 107.42%. On the other hand Nuwellis has an analysts' consensus of -- which suggests that it could grow by 1500%. Given that Nuwellis has higher upside potential than Quanterix, analysts believe Nuwellis is more attractive than Quanterix.

Quanterix has a beta of 1.300, which suggesting that the stock is 29.975% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.488%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are larger than Nuwellis quarterly revenues of $2.4M. Quanterix's net income of -$9.5M is lower than Nuwellis's net income of $2.4M. Notably, Quanterix's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 3.12x versus 0.06x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -27.76% compared to Quanterix's net margin of -24.31%. Quanterix's return on equity of -11.45% beat Varex Imaging's return on equity of -8.23%.

Quanterix has a consensus price target of $21.80, signalling upside risk potential of 107.42%. On the other hand Varex Imaging has an analysts' consensus of -- which suggests that it could grow by 57%. Given that Quanterix has higher upside potential than Varex Imaging, analysts believe Quanterix is more attractive than Varex Imaging.

Quanterix has a beta of 1.300, which suggesting that the stock is 29.975% more volatile than S&P 500. In comparison Varex Imaging has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.736%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are smaller than Varex Imaging quarterly revenues of $205.7M. Quanterix's net income of -$9.5M is higher than Varex Imaging's net income of -$50M. Notably, Quanterix's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 3.12x versus 0.72x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.